09:19 ET - Baxter International has a little more than two weeks to figure out what to relay to investors about the extent to which tariffs will affect its business. The medical-products maker will have a conference call Feb. 20 to discuss its 4Q results. Its guidance for 2025 will garner more attention in the wake of broad tariffs that President Trump has levied against Mexico, Canada and China set to go into effect Tuesday. Baxter on Monday noted its 2025 adjusted operating margin view of 16.5% doesn't include any impact from such tariffs. The company added it's working to quantify the expected impact of such tariffs, as well as identify potential mitigation opportunities, and will provide an update on its 4Q call. Shares edge down 2.3% to $31.81 in premarket trading. (denny.jacob@wsj.com; @pennedbyden)
(END) Dow Jones Newswires
February 03, 2025 09:19 ET (14:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。